SCM
IMVT icon

Superstring Capital Management’s Immunovant IMVT Stock Holding History

Superstring Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.88M Buy
357,606
+68,929
+24% +$1.78M 6.35% 2
2025
Q4 		$7.34M Sell
288,677
-52,671
-15% -$1.17M 3.93% 7
2025
Q3 		$5.5M Buy
+341,348
New +$5.53M 5.42% 5
2024
Q4 		– Sell
-12,447
Closed -$355K – 44
2024
Q3 		$355K Buy
+12,447
New +$367K 0.31% 25
2024
Q1 		– Sell
-203,592
Closed -$8.58M – 39
2023
Q4 		$8.58M Buy
+203,592
New +$7.49M 6.12% 7

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Superstring Capital Management's IMVT Position: Q1 2026 in Review

Superstring Capital Management increased its Immunovant (IMVT) stake by 24% in Q1 2026, buying an estimated $1.78M and bringing the position to 357,606 shares worth $8.88M. The position accounts for 6.35% of the portfolio, ranked #2.

Superstring Capital Management first reported a position in IMVT in Q4 2023 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Superstring Capital Management held 357,606 shares of Immunovant worth $8.88M as of Q1 2026.
  • Superstring Capital Management bought 68,929 Immunovant shares in Q1 2026, an estimated $1.78M.
  • Immunovant made up 6.35% of Superstring Capital Management's portfolio in Q1 2026, its #2 holding.
  • Superstring Capital Management first reported a position in Immunovant in Q4 2023 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.